Introduction
H uman embryonic stem cells (hESCs) are an emerging cell source for fi brocartilage tissue engineering [1] . These cells are exciting for tissue engineering applications as they have unlimited proliferative capacity and are multipotent [2, 3] . Moreover, in the future, there is great potential for using these cells in patient-specifi c therapies, either through hESC banks or through somatic cell nuclear transfer [4, 5] . Creating functional fi brocartilages, such as the temporomandibular joint disc, intervertebral disc, and the knee meniscus, requires that these multipotent cells be differentiated down a fi brocartilaginous lineage. Determining effi cient and effi cacious methodologies for differentiation is a critical goal for the fi eld.
One way to recreate the cues needed for differentiation is through modifying the growth medium, and such cues can be taken from fi brocartilage, as well as cartilage-related literature. Differentiation down a cartilaginous lineage, as well as other lineages, can occur spontaneously through culture without specifi c differentiation treatments [6] . To make this differentiation more effi cient and enhance cartilaginous matrix production, many groups are employing a "chondrogenic" base medium consisting of ITS+ [insulin, transferrin, selenium, and bovine serum albumin (BSA)], dexamethasone, ascorbic acid, and pyruvate [7] [8] [9] [10] . Using the immense research with adult progenitor cells and primary cells as a guide, recent work has largely focused on supplementing this chondrogenic medium with growth factors from the transforming growth factor-β (TGF-β) superfamily. Levenberg et al. [11] used TGF-β1 to create cartilaginous matrix in hESC-seeded scaffolds and Toh et al. [12] found that supplementation with bone morphogenic protein-2 (BMP-2) increased glycosaminoglycans (GAG) and collagen II staining in hESC embryoid body (EB) outgrowths. In contrast, one study showed that chondrogenic medium alone outperformed two different differentiation regimens using sequential dosing of TGF-β3, TGF-β1, IGF-1, and BMP-2 [13] . Studies of hESC-derived cells and human embryonic germ cells have shown benefi ts with TGF-β growth factors (β1 or β3), while
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the study, we compare hESC cocultures with primary articular chondrocytes and meniscal fi brochondrocytes. We hypothesize that cocultures lead to increased specifi c collagen production. Finally, the most benefi cial growth factor and coculture methodology, as determined by fi brocartilaginous protein production, are studied in combination. In this fi nal phase, the hypothesis is that the combination outperforms either treatment alone. "Spin embryoid bodies" [34, 35] of H9 hESCs are utilized to allow for uniform differentiation and analysis at the protein level to determine differentiation toward a fi brocartilaginous lineage. Looking toward future work with the differentiated cells, we also analyze an array of cell surface markers to identify markers predictive of protein production. Specifi cally, (1) CD44, the hyaluronan receptor and an important mesodermal marker; (2) CD105, the TGF-β3 receptor; (3) platelet-derived growth factor receptor α (PDGFRα), a mesodermal marker; and (4) SSEA-4, marker of undifferentiation in hESCs [3, 20, [36] [37] [38] .
Materials and Methods

hESC culture
H9 hESCs (abbreviated "H9"; Wicell, Madison, WI, USA) were cultured according to the manufacturer's instructions on irradiated CF-1 mouse embryonic fi broblasts (MEFs) (Charles River Laboratory, Wilmington, MA, USA). Colonies were passaged using 0.1% type IV collagenase (Invitrogen, Carlsbad, CA, USA) every 4-6 days. Colonies were passaged on to Matrigel (BD Biosciences, San Jose, CA, USA) coated plates for the fi nal passage before EB formation. While on Matrigel, the colonies were given MEF-conditioned medium supplemented with basic fi broblast growth factor (bFGF; Invitrogen).
Spin EB formation
Spin EBs [34, 35] were prepared by lifting cells off the Matrigel with 4 min of 0.05% trypsin with EDTA (Invitrogen) application. Trypsin was stopped with hESC medium, the cells were counted and seeded at 1 × 10 5 cells/100 μL of bFGF-supplemented conditioned medium into lowadherence V-bottom 96-well plates (Sarstedt, Newton, NC, USA). The plates were centrifuged for 5 min at 950g. The plates were then allowed to incubate for 48 h. Spin EBs were lifted out of the wells with gentle pipetting and resuspended in appropriate medium for differentiation in six well plates, at approximately 20-30 EBs/well. Culture plates were coated in 2% agarose to prevent EBs from adhering to the well bottom.
Differentiation treatments
The base chondrogenic medium contained 1% fetal bovine serum (FBS) (Gemini, West Sacramento, CA, USA), DMEM with 4.5 g/L glucose and l-glutamine (Invitrogen), 1% nonessential amino acids, 0.4 mM proline, 50 μg/mL l-ascorbate-2 phosphate (Sigma, St. Louis, MO, USA), 100 μg/mL sodium pyruvate (Sigma), 1% ITS+ (BD Biosciences), and 100 nM dexamethasone. Growth factor treatments included TGF-β3 (Peprotech, Rocky Hill, NJ, USA), PDGF-BB (Peprotech), rhSHH-N (R&D Systems, Minneapolis, MN, combinations with BMP-2 were not benefi cial [14, 15] . A larger variety of growth factors have been tried with mouse embryonic stem cells (mESCs), but the results have been mixed with respect to the most effective combination and dosing of TGF-βs and BMPs [16] [17] [18] [19] . Other growth factor combinations including TGF-β3 + PDGF-BB and TGF-β1 + BMP-4 have also shown promise in mESC studies toward enhanced collagen II and GAG production [20] . Additional growth factors that have shown signifi cant capacity to differentiate adult progenitors include BMP-6 and sonic hedgehog (SHH) protein [21] [22] [23] [24] [25] . As can be seen from the array of data, there is, as of yet, no gold standard for the differentiation of embryonic stem cells with growth factor combinations.
Another methodology for recapitulating the microenvironment milieu of development is coculture with primary cells. One study examined hESCs grown on inserts over "feeder layers" of fi rst passage nasal chondrocytes [26] . The cells were cocultured for 4 weeks before implantation in a nude mouse in PDLLA foam scaffolds. The cocultured implants were found to have increased GAG and collagen, as well as a greater collagen II/I ratio over controls. Similar cocultures with varying degrees of contact between primary cells (intervertebral disc) and adult progenitor cells have also been used toward fi brocartilage applications [27, 28] . One challenge with this approach is that it requires appropriate primary cells. However, the advantage is that the primary cells are more capable of recreating the complex biochemical signaling environment that may be needed for differentiation.
In this study, a wide range of differentiation conditions are studied with the objective of differentiating hESCs to cells that produce fi brocartilaginous extracellular matrix (ECM). Differentiation to "fi brochondrocytes" per se is not reasonable because specifi c markers are yet to be identifi ed for a fi brochondrocyte. However, a functional defi nition of fi brocartilaginous differentiation can be applicable for tissue engineering purposes where the goal is functional restoration. Fibrocartilage is composed of varying ECM based on the region of the tissue. For example, the inner third of the meniscus contains collagen II while the outer portion is predominantly collagen I, with smaller amounts of type VI [29] [30] [31] [32] . To engineer such a complex and heterogeneous tissue, it will be necessary to differentiate hESCs to cells capable of producing these types of matrix in varying ratios. This is a three-phase study examining differentiation through the use of (1) growth factors, (2) coculture conditions, and (3) the combination of the most effective growth factor and coculture regimens. In the fi rst phase, we initially compare control chondrogenic medium to medium supplemented with TGF-β3, chosen over TGF-β1 because of its enhanced potency [33] , to determine whether TGF-β3 treatment is benefi cial compared to chondrogenic medium alone. Next, TGF-β3 treatment is combined with varying concentrations of PDGF-BB, SHH, BMP-2, BMP-4, and BMP-6 to further increase fi brocartilaginous matrix production. Specifi c hypotheses include the following: (1) TGF-β3 enhances fi brocartilaginous matrix production; (2) the performance of TGF-β3 is enhanced by combinations with other factors, including BMPs, PDGF-BB, and SHH; (3) combinations with BMPs specifi cally increase GAG production; and (4) combination specifi cally with BMP-4 in addition increases collagen production. In the second phase of 10 mM HEPES, and 50 μg/mL l-ascorbic acid (Sigma). To obtain suffi cient cells for the experiment, cells from three animals were frozen at -80ºC and later pooled to create a mixed animal primary cell population. Cocultures were prepared by thawing cells into a T-75 tissue culture-treated plastic fl ask (BD Biosciences) for 48 h; cells were then collected by trypsinization and irradiated with 6,000 rads. Cells were seeded at 5 × 10 5 cells per well of a 6-well plate. To separate EBs from the feeder layers, nylon mesh cell strainers were coated along the bottom and sides with 2% agarose (Sigma). EBs were then placed within the strainers. The agarose coating created a barrier between the EBs and the feeder layer while allowing diffusion of media and proteins (Fig. 1) . Control treatment EBs were grown on agarose-coated wells or agarose-coated cell strainers.
For all treatments, half medium changes were made every 3 days. New feeder layers were prepared each week. EBs were cultured a total of 3 weeks before analysis.
Immunohistochemistry and histology
Samples were frozen and sectioned at 12 μm. Immunohistochemical analysis was performed by fi xing sections in chilled acetone, rehydrating, treating with 3% H 2 O 2 in methanol, and blocking with horse serum. The following primary antibodies were diluted in PBS and applied for 1 h: 1:100 rabbit anti-human collagen VI pAb (US Biological, Swampscott, MA, USA), 1:750 rabbit anti-human collagen II pAB (Cedarlane, Burlington, NC, USA), and 1:650 mouse anti-human collagen I (Chondrex, Redmond, WA, USA). Visualization using a secondary biotinylated antibody, the ABC reagent, and DAB was performed using the Vectastain kit (Vector Laboratories, Burlingame, CA, USA), and counterstaining was done with Harris's hematoxylin. Sections of articular cartilage and meniscal fi brocartilage were run as positive controls, while samples were stained without application of the primary antibody as negative controls. To determine whether undesired differentiation had occurred, Von Kossa and oil red-O stains were performed for evidence of calcifi cation and adipose tissue, respectively. In addtion, both Alcian Blue and Safranin-O were employed as qualitative methods for demonstrating chondrogenesis.
Quantitative biochemistry
Samples were lyophilized for 48 h and digested in 125 μg/mL papain (Sigma) for 18 h at 60ºC. Cell number was determined using Picogreen Cell Proliferation Assay Growth factor treatments and primary cell cocultures have been studied extensively in the past with mESCs and adult stem cells for chondrogenic differentiation. We approached the study of differentiation treatments in three phases: (1) USA), BMP-4 (Peprotech), BMP-2 (Peprotech), and BMP-6 (Promokine, Heidelberg, Germany). Low (L) and high (H) concentrations for each growth factor and the applied combinations are described in Table 1 . All growth factors were diluted in accordance with the instructions from the manufacturer.
The primary cells for feeder layers, meniscal fi brochondrocytes and articular chondrocytes, were harvested from the inner two-thirds of the medial meniscus and the distal femora, respectively, of approximately 1-week-old male calves (Research 87, Boston, MA, USA) <36 h after slaughter. Tissue was minced and digested overnight with 0.2% collagenase II (Worthington, Lakewood, NJ, USA) in 10% FBS culture medium. The FBS culture medium is DMEM with 4.5 g/L glucose and l-glutamine (Gibco, Grand Island, NY, USA), 10% FBS (Gemini), 1% fungizone, 1% penicillin/ streptomycin, 1% nonessential amino acids, 0.4 mM proline, Kit (Molecular Probes, Eugene, OR, USA). A hydroxyproline assay was performed to gauge total collagen using bovine collagen standards (Biocolor, Newtonabbey, Northern Ireland). After fi nding positive Alcian Blue and Safranin-O staining, we then proceeded to quantify the GAG and other matrix production through a sulfated GAG assay using the Blyscan GAG Assay Kit (Biocolor). For each assay, 5-10 samples were analyzed. Data are reported as total matrix produced normalized to that produced by control or TGF-β3, as well as total matrix divided by the number of cells in the EB to give marix production per cell.
Samples for enzyme-linked immunosorbent assay (ELISA) were digested in papain at 4ºC for 4 days and then a 1/10 volume of elastase (Sigma) solution in 10× TBS buffer was added to achieve a concentration of 0.1 mg/mL elastase. Samples were allowed to digest an additional 48 h. Between each incubation step in the ELISA, plates were washed using PBS with 0.05% Tween-20. For the collagen I ELISA, plates were incubated overnight at 4°C with 1:400 mouse anti-human capture mAb (US Biological), blocked with 2% BSA, samples and standards were added, then exposed to rabbit anti-human pAb (US Biological). Finally, goat antirabbit pAb was added, and the color developed in TMB as a liquid peroxidase substrate. The collagen II ELISA was performed using the Chondrex (Redmond, WA, USA) capture mAb, the Chondrex-biotinylated mAb, and streptavidin peroxidase was used with TMB to develop the color. Absorbance was read at 450 nm in a Genios plate reader (Tecan, San Jose, CA, USA). For the ELISAs, 4-8 samples were analyzed.
Flow cytometry
The best performing differentiation treatments from each phase were selected for fl ow cytometry analysis. EBs were analyzed 48 h after formation ("undifferentiated") and after 3 weeks of differentiation treatment. Three samples were prepared per treatment per primary antibody. EBs were digested to obtain a single cell suspension, by applying trypsin for 1 h, followed by 0.2% type II collagenase (Worthington). The collagenase digestion was terminated when undigested material was no longer visible (1-1.25 h). Cells were blocked with goat serum, and the following primary antibodies were applied at 10 μg/mL for 30 min: mouse IgG isotype control (Invitrogen), mouse anti-human PDGFRα (R&D Systems), mouse anti-human CD44 (Sigma), or mouse anti-human CD105 (Invitrogen). In addition, mouse antihuman SSEA-4 (Developmental Studies Hybridoma Bank) was applied at 0.6 μg/mL. Cells were washed in PBS, and then the Alexa Fluor 488 goat anti-mouse FITC (Molecular Probes, Carlsbad, CA, USA) was applied for 30 min. Samples were fi xed in 0.5% paraformaldehyde, and stored at 4°C until analysis. Samples were run on a FACSCalibur fl ow cytometer (BD Biosciences). Data were analyzed for forward scatter and the percentage of cells labeled at a fl uorescence level exceeding a 95% threshold on the isotype control.
Statistics
All data were compiled as mean ± standard deviation and a one-factor ANOVA was used to examine means from the quantitative biochemistry and fl ow cytometry data. If analysis showed a signifi cant difference, a Tukey's post hoc or Student's t-test analysis was performed. A signifi cance level of p < 0.05 was used in all statistical tests performed. The R 2 values were calculated using linear regression of the data sets under evaluation [39] .
Results
Growth factor differentiation
TGF-β3 treatment resulted in a signifi cant 60% increase in GAG production over control (Fig. 2) . There was no signifi cant difference between the control and the TGF-β3-treated group in total collagen or collagen II quantity. Immunohistochemistry indicated very faint and nonuniform staining for collagen I, although no collagen I was detected by ELISA. As TGF-β3 showed benefi t toward fi brocartilaginous differentiation, combinations of this growth factor were tested with varying concentrations of (1) PDGF-BB or SHH and (2) BMP-2, BMP-4, or BMP-6. In the fi rst experiment, high and low concentrations of PDGF-BB or SHH were combined with TGF-β3, and all results were normalized to the TGF-β3-treated group. Immunohistochemistry showed the presence of collagen VI in all groups and collagen II was present in those treated with SHH. Quantitative biochemistry showed that there was no signifi cant change in cell number per EB or collagen II production for combination with either PDGF-BB or SHH (Fig. 3A) . In contrast, SHH treatment actually decreased GAG production compared to TGF-β3 alone. PH showed a 115% increase in total collagen production, and SHH showed a trend toward increasing collagen production. When normalized per cell, PH did not show improvement in collagen or GAG over TGF-β3 alone; only SH showed an increase in collagen per cell compared to TGF-β3. A comparison of BMPs combined with TGF-β3 netted greater improvements in matrix production. Immunohistochemistry demonstrated positive staining for collagen II and VI in all BMP-treated groups; however, collagen I was only present in 4H, 6L, and 6H (Fig. 4) . Only 4H showed an increase in cell number over TGF-β3 (Fig. 3B) . Both 2H and 4H showed increased GAG production, 6.1-and 6.7-fold increases, respectively. Only 4H showed a signifi cant 4.8-fold increase in collagen over TGF-β3 alone. There was no increase in collagen II with any treatment. Normalization per cell showed similar trends to the per sample data, with the exception of 6L showing signifi cantly greater collagen per cell compared to TGF-β3 alone. No collagen I was 
FIG. 2. TGF-β3 treatment resulted in increased GAG
synthesis over control (chondrogenic medium with no growth factor addition), while collagen II content trended higher. Taking an optimization approach, follow-up studies examined combinations with TGF-β3. *p < 0.05.
detectable by ELISA for these experiments; however, immunohistochemistry showed intense staining in the 4H group, and pale staining in the 6H group (Fig. 4) . Von Kossa and oil red-O staining for extraneous differentiation were negative (data not shown).
Coculture mediated differentiation
In a preliminary study, it was found that a primary cell feeder layer density of 5.0 × 10 5 cells/well showed more effect on matrix production than 2.5 × 10 5 cells/well (data not shown); therefore, the greater feeder density was utilized in the follow-up experiment. Culture of EBs in an agarose-coated cell strainer in the absence of a feeder was also compared to EBs grown in agarose-coated wells; no signifi cant differences were found between the groups for matrix production or cell proliferation (data not shown). Use of articular cartilage and meniscal fi brocartilage-derived feeder layers only signifi cantly increased specifi c collagen production (Fig. 5) . While collagen I was undetectable in all groups either through ELISA or immunohistochemistry, collagen type II content was 7-and 9-fold that of the control in the chondrocyte and fi brochondrocyte cocultures, respectively. These changes were similar when normalized to cell number. Von Kossa and oil red-O staining for extraneous differentiation were negative (data not shown). 
Combination of growth factor and coculture conditions
The combination treatment of BMP-4 + TGF-β3 and fi brochondrocyte coculture resulted in GAG and collagen content 7-and 2-fold, respectively, that of the control, as well as enhanced cell proliferation over control (Fig. 6A) . However, there was no signifi cant difference compared to the BMP-4 + TGF-β3 treatment alone. Collagen I, II, and VI were present as shown by immunohistochemistry (Fig. 6B) . When normalized to the cell content, no signifi cant differences were found. Von Kossa and oil red-O staining for extraneous differentiation were negative (data not shown).
Flow cytometry
Undifferentiated EBs and EBs treated with control medium, BMP-4 + TGF-β3, and a fi brochondrocyte coculture were analyzed for the presence of four cell surface markers (Fig. 7) . The selected differentiation treatments were the highest protein producers determined in each phase. Only the growth factor combination signifi cantly increased CD44, 32.2 ± 1.9% positive. Both undifferentiated cells and growth factor combination-treated cells showed increased CD105, at 14.3 ± 3.2% and 17.9 ± 1.0% positive, respectively. All of the treatment groups showed signifi cant drops in SSEA-4 compared to undifferentiated cells. The forward scatter, given as dimensionless measures of mean fl uorescence intensity, offers a gauge of cell size (from largest to smallest): for the BMP-4 + TGF-β3 groups it was 693 ± 39, 578 ± 2 for the undifferentiated cells, 490 ± 14 for fi brochondrocyte cocultured cells, and 466 ± 17 for control-treated cells (see Supplementary Fig. 1 , available online at http:// www.liebertpub.com/rej). The combination treatment produced cells with similar levels of surface markers and size distribution to those resulting from the BMP-4 + TGF-β3 treatment (data not shown).
Discussion
Fibrocartilage tissue engineering with hESCs is in its infancy; this study is the fi rst to examine a large variety of growth factor combinations and cocultures specifi cally toward fi brocartilage differentiation. Earlier work has identifi ed an appropriate hESC line and differentiation time [1] and in this study, a three-phase approach was taken to refi ne the differentiation process. First, growth factor treatments were compared and TGF-β3 was found to enhance GAG synthesis, while its combination with BMP-4 was found to increase GAG, total collagen, and collagen type I production. In the second phase, this study found that coculture with fi brochondrocytes successfully induced greater collagen II production over control or articular chondrocyte cocultures. Combinations of TGF-β3 with PDGF-BB or SHH were found to be less fruitful. In the third phase, combining the best performing growth factor combination with the coculture resulted in a trend of increased GAG and collagen synthesis over either treatment alone. Flow cytometry analysis showed that the treatments differentially affected the cell surface geography and cell size, demonstrating a powerful link between protein production and cell size and surface markers. Overall, we have identifi ed a treatment, BMP-4 + TGF-β3, that results in enhanced synthesis of important fi brocartilaginous proteins, while using a coculture with fi brochondrocytes markedly increases collagen II production. Moreover, increased CD44, maintenance of CD105 levels, as well as marked differences in cell size indicate that future work purifying these cells may be possible.
The utility of TGF-β3 in enhancing GAG synthesis correlates well to several previous studies of hESCs, mESCs, and other similar cell lines [11, 15, 16, 20, 40] . The lack of enhanced collagen II production or GAG synthesis when TGF-β3 was combined with PDGF-BB or SHH was surprising, given evidence with mesenchymal stem cells (MSCs) and mESCs to support these combinations [20, 21] . SHH acts upstream of TGF-β signaling and is known to increase the expression of TGF-β isoforms [41, 42] . One hypothesis for the lack of response is that the TGF-β3 concentration used here was already at a saturation level. Future work may study whether SHH could be more effective in the presence of BMPs, as downstream expression of BMP receptors has been shown [43] .
Three different BMPs were examined in this study since each has shown utility in different systems; for example, BMP-2 combined with TGF-β3 outperformed similar combinations with BMP-4 and BMP-6 in a study of MSCs [44] ; BMP-6 appears to be particularly effective with adipose-derived progenitor cells compared to BMP-2, BMP-4, and BMP-7 [23, 24] , while BMP-4 has outperformed BMP-2 in mESC chondrogenesis [20] . The large increases in fi brocartilaginous matrix synthesis seen in this study with BMP-2 or BMP-4 combined with TGF-β3 contrasts with recent work with hESC-derived cells [15, 16] but are supported by work with mESCs [18, 20] . Additional studies with adult progenitors, both bone marrow and adipose derived, also show positive and even synergistic results in combining a TGF-β growth factor with a BMP [23] [24] [25] 45] . The increases in GAG and collagen seen in this study may have been due to direct effects of the BMPs, BMP-induced increases in TGF-β receptors [24] , or a combination of these two effects. Overall, combinations of TGF-β3 and BMP-4 merits greater study as the increases in matrix, 6.7-fold in GAG and 4.8-fold in collagen compared to TGF-β3 alone, were signifi cant. Although this study examined a dose range covering most previously studied concentrations of BMPs, 20-100 ng/mL, a dose-response was still observed; thus, a saturation concentration may still need to be identifi ed.
An alternative to growth factor-mediated differentiation is the use of cocultures to provide the biochemical stimuli for differentiation. In using primary cells, there are the added challenges of an appropriate source and varying potency of the primary cells. Despite these considerations, cocultures may provide a powerful stimulus, one that may even be responsive to the signals given off by the differentiating cells; i.e., there is opportunity for cross-talk between the two cell populations. It was hypothesized in this study that the cocultures would differentially regulate specifi c collagen production as the cells themselves have very different collagen synthesis profi les, and, interestingly, both cell types appeared to increase collagen II production with little effect on collagen I. The 7-to 10-fold increase in collagen II production is an important advance in fi brocartilaginous differentiation. Earlier work with nasal chondrocytes cocultured with the hESC H1 line showed large increases in GAG production and collagen II staining [26] . Future work will further examine appropriate "dosing" of the coculture, including issues such as cell density, how often new feeder layers should be prepared, and whether feeder layers should be treated with growth factors or other stimuli. In addition, recent studies using chondrocyte-conditioned medium to differentiate MSCs [28, 46] or the mixing of MSCs and primary cells [28, 47, 48 ] also show promise. Future work comparing conditioned medium, direct mixing of the cells, and the set-up used in this study in which the two cell populations were separated by a protein-permeable barrier will help further elucidate the role of cross-talk between the progenitor cells and primary cells. Moreover, in this study, a cross-species coculture was utilized because of convenience in cell procurement; future studies must look toward comparing different sources of primary cells for cocultures in terms of their practicality and especially the elimination of source-to-source variation in the level of stimulus provided.
One of the prominent challenges in using a coculture is that there may be variation in the differentiating capacity of the primary cells used in the cocultures, especially if taken from different donors. This variation may explain the results of the combination growth factor-coculture study (phase 3) versus the coculture alone study (phase 2). Although coculture cells were pooled from multiple animals for each phase, there may have been variation in the differentiating capacity of these two pooled populations of cells. This variation was evidenced by the large increases in collagen II measured in phase 2 while these increases in collagen II quantity were not reproduced in phase 3. In contrast, the increases in collagen and GAG, expected with the use of the growth factors, were observed in both phases. The coculture clearly played a role in terms of mitogenic stimulation, as the combination treatment resulted in a large increase in cell number. Future work utilizing cell lines may enhance the consistency of this differentiation tool. However, coculture with patient-derived cells may be more appropriate for future therapeutic use. In such a case, examination and assessment of the differentiating capacity of cocultures will be critical as cocultures can clearly serve as powerful differentiation stimuli.
The fl ow cytometry component of this study was undertaken as a fi rst evaluation of an important tool for later studies: purifying populations of differentiated cells. Flow cytometry analysis may also be a powerful tool to identify a marker indicative of fi brocartilaginous matrix production, which could be used to screen large numbers of differentiation strategies rather than laborious and expensive protein-level analyses. First, we used SSEA-4 expression as a gauge of whether the cells had retained their multipotency. As expected, there was a 70-80% drop in this marker during the differentiation period studied. We then examined three other cell surface markers that have been linked to chondrogenesis: PDGFRα, CD44, and CD105. Although PDGFRα+ mESCs have shown signifi cant increases in chondrogenesis [20] , none of the treatments markedly changed PDGFRα expression in this study. A particularly promising potential marker for cartilaginous differentiation is CD44; this marker appears early in chondrogenesis and is important in the formation of chondrocyte pericellular matrix [49] [50] [51] . This marker has also been correlated to increased chondrogenicity in adult chondrocyte populations [38, 52] . Of the markers examined, CD44 was the only one that signifi cantly increased over the undifferentiated and control treatment populations. We can speculate that increased presence of this hyaluronan receptor correlates with the enhanced GAG production seen in the EBs created with the BMP-4 + TGF-β3 treatment (R 2 = 0.78). Furthermore, since increased GAG was not seen with the fi brochondrocyte coculture, it is consistent that CD44 was not increased. It was hypothesized that CD105 would increase with TGF-β3 treatment and be a positive indicator of fi brochondrogenesis. Comparisons between the BMP-4 + TGF-β3 group and the control/coculture groups, which were not treated with TGF-β3, support this hypothesis. The lack of difference between the undifferentiated cells and the BMP4 + TGF-β3 group suggests that the treatment led to the maintenance of this cell surface maker, while in the other groups, the marker was lost during culture. Thus, CD105 could be used as a differentiation indicator only after the cells have been purifi ed of cells expressing undifferentiation markers. The presence of CD105 has been used before differentiation to isolate a chondrogenic population; by maintaining the presence of this surface marker, the BMP4 + TGF-β3 treatment may have had increased effi cacy in fi brocartilage differentiation [37] . These data lay a foundation for using fl ow cytometry to purify particularly promising populations for chondrogenesis. For example, treated cells could fi rst be purifi ed to remove all SSEA-4+ cells, and then sorted to obtain a CD44+ and CD105+ population. As this study cannot show to what degree these populations overlap, such an examination will be important to more concretely establish these markers for chondrogenesis.
This work shows signifi cant gains in fi brocartilage matrix synthesis in hESC EBs comparing 15 differentiation strategies. The combination of BMP-4 + TGF-β3 was effective in stimulating production of collagens I, II, and VI, and markedly increasing total collagen and GAG production. It was also demonstrated that BMP-4 + TGF-β3 differentiated hESCs posses a greater forward scatter (gauge of cell size) and the highest CD44 presence compared to the other groups; both of these changes may serve as important markers for purifying these cells. These refi ned methods for differentiation can now be applied in a tissue engineering strategy to create hESC-derived fi brocartilage.
